NeuMoDx Archives | Arboretum Ventures

Home Page NeuMoDx News Page

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

QIAGEN today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular,…

Arboretum_JDSeptember 17, 2020

NeuMoDx News Page

NeuMoDx Molecular Announces CE Mark for HPV Diagnostic Test

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it…

Arboretum_JDJuly 20, 2020

Home Page NeuMoDx News Page

NeuMoDx Plans Saliva Sample Extension for SARS-CoV-2 Test Emergency Use Authorization

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to…

Arboretum_JDMay 7, 2020

NeuMoDx News Page

NeuMoDx Announces CE Marking for SARS-COV2 Test

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to…

Arboretum_JDMay 4, 2020

NeuMoDx News Page

NeuMoDx Announces US FDA Emergency Use Authorization (EUA) for SARS-CoV2 Test

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to…

Arboretum_JDMarch 31, 2020

NeuMoDx News Page

NeuMoDx Preparing to Launch Coronavirus Test for its Fully Automated Testing Systems

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and…

Arboretum_JDMarch 12, 2020

NeuMoDx

NeuMoDx™ Plans to Add CE-IVD Assay for HPV

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today an…

Arboretum_JDOctober 21, 2019

NeuMoDx News Page

NeuMoDx Gets CE Mark on Hepatitis B and C Assays

NeuMoDx confirmed today it has received CE-IVD marking on assays to detect and quantify levels…

Arboretum_JDJune 26, 2019

Home Page NeuMoDx News Page

QIAGEN and NeuMoDx Announce Strategic Partnership to Offer Next-Generation Systems for Fully Integrated Molecular Diagnostic Testing

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced a…

Arboretum_JDSeptember 17, 2018

NeuMoDx News Page

NeuMoDx Molecular Announces FDA 510(k) Clearance for its N288 Molecular System and GBS Assay

NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it…

Arboretum_JDAugust 8, 2018

NeuMoDx

QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems

NeuMoDx Molecular Announces CE Mark for HPV Diagnostic Test

NeuMoDx Plans Saliva Sample Extension for SARS-CoV-2 Test Emergency Use Authorization

NeuMoDx Announces CE Marking for SARS-COV2 Test

NeuMoDx Announces US FDA Emergency Use Authorization (EUA) for SARS-CoV2 Test

NeuMoDx Preparing to Launch Coronavirus Test for its Fully Automated Testing Systems

NeuMoDx™ Plans to Add CE-IVD Assay for HPV

NeuMoDx Gets CE Mark on Hepatitis B and C Assays

QIAGEN and NeuMoDx Announce Strategic Partnership to Offer Next-Generation Systems for Fully Integrated Molecular Diagnostic Testing

NeuMoDx Molecular Announces FDA 510(k) Clearance for its N288 Molecular System and GBS Assay

News & Insights

ARCHIVES